FDA accepts Depomed's DM-1796 NDA for pain after shingles

Jun 8 2010NewsGuard 100/100 Score

Depomed, Inc. (Nasdaq:DEPO) today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

"We are pleased the NDA was accepted for DM-1796. The acceptance triggers a $10 million milestone payment from our licensee," said Carl Pelzel, president and chief executive officer of Depomed. "We look forward to the approval of DM-1796, which we believe can provide significant clinical benefits to patients."

SOURCE Depomed, Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Weight loss drug semaglutide may offer relief for knee arthritis pain
How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics
It's official! Men and women experience and manage pain differently
Higher zinc intake linked to increased endometriosis risk, study finds
Telehealth mindfulness interventions significantly improve chronic pain outcomes for veterans
Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps
Small Solutions for Big Problems in Drug Discovery and Delivery
Physical activity and positive affect boost cognition in women with fibromyalgia despite pain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Myocarditis risks linked to COVID-19 vaccination explained